Kornimate/medical-research-clean huggingface dataset:
artificial urinary sphincter clinical outcomes

Conditions: Stress Urinary Incontinence

Summary: to evaluate the ams 800 artificial urinary sphincter (aus) in men with primary stress urinary incontinence as measured by pad weight tests.


Eligibility criteria:
inclusion criteria: 1. male 2. ≥ 18 years of age 3. has undergone either a radical prostatectomy, transurethral resection of the prostate or other invasive prostate surgery 4. demonstrates primary stress urinary incontinence 5. positive screening 24-hour pad weight test (≥100 grams) 6. experiences at least 3 incontinence episodes per day during baseline diary or presents with continuous incontinence 7. negative urine culture 8. willing and able to undergo surgical implantation of the aus device 9. willing and able to comply with the follow-up requirements 10. willing and able to forego any other surgical urinary incontinence treatments while participating in the study 11. willing and able to sign the informed consent exclusion criteria: 1. previously had or currently has a device implanted (aus/sling, or otherwise) for treatment of sui or urge incontinence 2. primary urgency incontinence 3. postvoid residual volume greater that 150 ml or a history of difficulty emptying the bladder 4. recurrent vesicourethral anastomotic stricture or urethral stricture disease within the past 6 months 5. known urogenital malignancy other than previously treated prostate cancer 6. recurrent prostate cancer that is expected to require intervention during the study follow-up period 7. history of recurrent bladder stones within the past 12 months prior to signing the informed consent 8. neurogenic bladder 9. need for intermittent catheterization 10. known history of bleeding diathesis or coagulopathy 11. immunosuppressed or on medical therapy which would impact the immune system 12. uncontrolled diabetes, defined as (hba1c\>10) 13. has a genitourinary mechanical prosthesis that was implanted within 3 months from the date of consent 14. had a post-implantation infection associated with the device after genitourinary mechanical prosthesis was implanted 15. undergone bulking procedure within 6 months of the baseline assessment 16. poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions 17. urinary incontinence due to or complicated by an irreversibly obstructed lower urinary tract 18. irresolvable detrusor hyperreflexia or bladder instability 19. currently enrolled or plans to enroll in another device or drug clinical trial 20. currently using an indwelling catheter or condom catheter for treatment of incontinence and is not willing to discontinue use at least 4 weeks prior to baseline assessment 21. known allergy or sensitivity to rifampin or to minocycline hcl or other tetracyclines (only applicable when implanting with inhibizone version of this device) 22. systemic lupus erythematosus because minocycline hcl has been reported to aggravate this condition (only applicable when implanting with inhibizone version of this device)
development and application of a new balloon catheter for intraairway hemostasis

Conditions: Hemoptysis

Summary: massive hemoptysis is a serious disease of respiratory system, which seriously endangers the life of patients. there are obvious difficulties in the treatment of hemoptysis. in the traditional treatment, patients still have the risk of massive hemoptysis and suffocation, and the risk control in the treatment process cannot be ensured. intra - airway interventional therapy, especially the hemostatic technique of intra - airway balloon catheter, is an important means to control the risk of hemoptysis. however, the current intraairway balloon catheter therapy technology is immature, complicated and difficult to operate, and the cost is high. there is a lack of special balloon for hemostasis, and the balloon borrowed for other purposes cannot meet the needs of hemoptysis treatment. therefore, it is urgent to develop a new balloon catheter for airway hemostasis, which has simple technical operation, easy to master and popularize, efficient and safe function and structure. according to this requirement, this project designed and developed hemostatic balloon catheter with multiple functions such as self-guiding, anti-displacement, anti-leakage and detachable rear end, so as to make the treatment of massive hemoptysis more safe and effective, simpler and faster, so as to be widely applied in clinical practice.

this study are aimed to investigate the safety and effectiveness of the new intraairway hemostatic balloon catheter in the treatment of massive hemoptysis, as well as the superior efficacy compared with the traditional treatment strategy of massive hemoptysis.

Eligibility criteria:
inclusion criteria: * the patients were 18-75 years, male or non-pregnant female; * meet the clinical definition of massive hemoptysis (blood loss ≥100ml each time or ≥500ml 24h); * the patient/legal authorized representative understood the purpose and procedure of the test and voluntarily signed the informed consent. exclusion criteria: * patients and their family members have no subjective treatment intention;patients fail to cooperate or sign preoperative informed consent; * the obvious effect of balloon catheter therapy is not ideal; * severe arrhythmia, acute myocardial ischemia; * blood pressure is not effectively controlled (diastolic blood pressure ≥95mmhg or systolic blood pressure ≥150mmhg); * severe coagulopathy; * severe organ insufficiency (except respiratory insufficiency); * allergic to narcotic drugs; * pregnant women, those who are breast-feeding or trying to conceive; * patients who do not wish to sign informed consent; * patients who failed to follow up; * other patients deemed unsuitable for the study by the investigator.
artificial intelligence-assissted glaucoma evaluation

Conditions: Artificial Intelligence; Glaucoma

Summary: glaucoma is currently the second leading cause of irreversible blindness in the world. our study intends to combine clinical data of glaucoma patients in zhongshan ophthalmic center with artificial intelligence techniques to create programs that can screen and diagnose glaucoma.

glaucoma is currently the second leading cause of irreversible blindness in the world, which brings heavy burden to human society. compared to other ocular diseases, diagnostic process of glaucoma is complicated depends on multiple test results, including visual field test, oct, etc. how to diagnose glaucoma correctly and fast has always been a hot topic in glaucoma researches. artificial intelligence is used to study and develop theories and methods that can help simulate and extend human intelligence, which has been utilized in a lot of research fields such as automatic drive and medicine. the study intends to combine clinical data of glaucoma patients in zhongshan ophthalmic center with artificial intelligence techniques to create programs that can screen and diagnose glaucoma.

Eligibility criteria:
inclusion criteria: 1. bcva\>0.1 2. able to complete reliable visual field test 3. no history of intraocular surgery or fundus laser exclusion criteria: 1. unable to complete visual field test

Keywords: artificial intelligence glaucoma
shoulder motion guided patient diagnostic and treatment classification

Conditions: Rotator Cuff Shoulder Syndrome and Allied Disorders

Summary: the investigators purpose is to determine the ability of a low cost, currently available imaging technique to predict shoulder movement disorders and the location of shoulder disease based on motion analysis of subjects with known shoulder disorders.

shoulder disorders account for the second largest number of musculoskeletal cases in the united states with a large health care burden. the current standard for diagnosis of shoulder disorders is a clinical exam, visual motion assessment and in some cases, costly magnetic resonance (mr) imaging. however, specific tissue pathologies are not always accurately identified, and often not directly linked to the magnitude of dysfunction. there is a need for categorizing or sub-grouping patients based on the underlying movement dysfunctions with which they present. video fluoroscopy is a common clinical tool that can improve the accuracy of motion analysis. the investigators are using 2-d fluoroscopy, combined with 3-d mr imaging to measure shoulder motion. from the motion analysis we can predict areas of potential soft tissue disease, and compare these to disease locations from mr imaging. the investigators hypotheses is that our motion based predicted disease locations will be significantly associated with disease locations from mr imaging.

Eligibility criteria:
inclusion criteria: * normal subjects with normal normal shoulder movement and function will be included, age and gender matched to symptomatic subjects. * symptomatic subjects will be included if visual shoulder movement deviates from what might be considered normal; they are experiencing shoulder pain with movement, and clinical examination is consistent with soft tissue cumulative trauma to the soft tissues (rotator cuff disease). * clinical mr imaging will be used to confirm rotator cuff disease, subacromial bursitis, and/or bicipital tendinitis. exclusion criteria: * age outside the accepted range. contraindications to radiation exposure (pregnancy or possible pregnancy, other recent substantive radiation exposures (ct scanning, treatments involving radiation). subjects unable to move through at least 90 degrees of shoulder motion will also be excluded.
the effectiveness of the exercise program applied by telerehabilitation method in individuals with chronic neck pain

Conditions: Neck Pain

Summary: neck pain is a common musculoskeletal problem occurring as one of the first conditions causing decreased quality of life and disability. an estimated 67.5% of people experience neck pain in their lives (5, 6). when the adult population is considered (15-74 years old), the prevalence ranges from 5.9% to 38.7%. causes of neck pain are largely variable, and include working in unsuitable ergonomic positions, sitting for a long time, and keeping the neck in abnormal physiological position for a long time. various factors are effective in the chronic stage of neck pain. neck pain is associated with decreased strength and endurance of the cervical muscles. it was observed that deep flexor muscles are weak and superficial flexor muscle activity is increased in patients with neck pain; and that exercise is effective in reducing neck pain because strength, endurance, and flexibility can be regained in the structures around the damaged tissue. there are several approaches that were found to be effective in the treatment of neck pain. these treatment strategies include physical therapy modalities, manual therapy, therapeutic exercise (stretching, strengthening, and endurance exercises) and home exercise programs. home exercise programs are used to expand the clinic-based physical therapy approaches to treat neck pain. it was stated that it is now compulsory to develop new rehabilitation models and practices to cope with global increase in elderly population, limited resources allocated to public health, and changes in population needs. telerehabilitation is recommended as a solution to provide physical therapy services; however, it was reported in previous studies that more studies are required in this field to accept its effectiveness. the purpose of the present study is to examine the effects of 4-week exercise protocol established with stretching, strengthening the scapula muscles for the neck and upper body, neck and core stabilization exercises by ensuring the follow-up of the patients with telerehabilitation method on patients' neck pain, daily life activities (dla), and quality of life by comparing its effects with individuals who apply only home program.


Eligibility criteria:
inclusion criteria: * voluntary individuals suffering from neck pain for at least 3 months * over the age of 18 * have a minimum score of 3/10 according to the numeric pain rating scale * who fill out the pain preliminary information form, and who will agree to participate in the study through this form. exclusion criteria: * pregnant women, * history of malignancy * congenital deformities or surgery history in the neck or shoulder area * perception problems for verbal commands * not having internet access * not having equipment to make video calls

Keywords: neck pain, telerehabilitation
effect of eye movement on toric lens orientation and visual acuity

Conditions: Astigmatism

Summary: the relative performance of a new toric soft contact lens against toric contact lenses currently available in market, specifically for visual acuity and lens orientation. the study will be conducted in a staged approach (2 stages).

non-dispensing, single-masked (subject-masked), randomised, controlled study. two visits.

Eligibility criteria:
inclusion criteria: 1. they are aged between 18-39 years. 2. they understand their rights as a research subject and are willing to sign a statement of informed consent. 3. they are willing and able to follow the protocol. 4. they can attain at least 6/9 in each eye with their spectacle refraction. 5. they have successfully worn contact lenses within six months of starting the study. 6. they can be fitted with toric soft contact lenses to match the available power range. exclusion criteria: 1. they have an ocular disorder which would normally contra-indicate contact lens wear. 2. they have a systemic disorder which would normally contra-indicate contact lens wear. 3. they are using any topical medication such as eye drops or ointment. 4. they are aphakic. 5. they have had corneal refractive surgery. 6. they have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. 7. they are pregnant or lactating. 8. they have grade 2 or greater of any of the following ocular surface signs: corneal oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear. 9. they have taken part in any other clinical trial or research, within two weeks prior to starting this study.

Keywords: astigmatism visual acuity orientation contact lenses
the effects of meditation on stress and fatigue

Conditions: Intensive Care Nurses

Summary: a randomized controlled trial was conducted with nurses practicing meditation for six weeks, compared to a control group with no intervention. stress and fatigue levels were measured using validated scales at baseline and post-intervention.

participants in the intervention group underwent a meditation practice for 20 minutes, three times a week for six weeks. the meditation sessions were led by a meditation expert with 8 years of experience and conducted online via whatsapp in a group setting. no intervention was given to the participants in the control group.

Eligibility criteria:
inclusion criteria: * intensive care nurses with at least 1 year of experience in the intensive care unit. * nurses without chronic obstructive pulmonary disease, heart failure, asthma, or other conditions that could hinder breathing exercises. * nurses without hearing and communication issues, psychiatric diagnoses (e.g., major depression). * nurses who have not attended meditation, yoga, or breathing exercise classes in the past six months. * nurses willing to participate in the study were included in the sample. exclusion criteria: * nurses who do not attend at least one of the meditation sessions conducted by the meditation expert.

Keywords: meditation stress fatigue intensive care nurses well-being
non interventional study of the validation of the ottawa score in cancer patients with venous thromboembolism (vte)

Conditions: Venous Thromboembolism

Summary: the purpose of this study is to validate the ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (innohep®)

the ottawa score is a clinical predictive score aiming at stratifying thromboembolic recurrences in cancer patients according to identified clinical risk factors and histological type of the tumor. this score has never been validated externally in a prospective way in patients treated with tinzaparin. the objective of this observational prospective study is to enroll cancer patients with ted treated with tinzaparin for a planned period of 6 months and to collect data on thromboembolic recurrences, major hemorrhages, deaths and heparin-induced thrombocytopenia

Eligibility criteria:
inclusion criteria: * cancer patients with histologically confirmed, active or evolving, solid or liquid tumour, or * suspected malignant tumour confirmed within a month of index vte occurrence * treated with specific metastatic or adjuvant anti-cancer treatment * patients with recent diagnosis of documented symptomatic or incidental vte and a prescription of tinzaparin for 6 months * proximal or distal vte of lower limbs * pulmonary embolism * inferior or superior vena cava thrombosis * iliac vein thrombosis exclusion criteria: * skin cancer other than melanoma * life expectancy less than 6 months * superficial isolated thrombosis * isolated subsegmental pulmonary embolism * cerebral, visceral thrombosis * superior limbs vte or central catheter thrombosis * patients being treated with anticoagulants by more than 7 days

Keywords: ottawa score tinzaparin low-molecular weight heparin anticoagulants venous thrombosis thromboembolism hemostatic disorders vascular disease neoplasms breast neoplasms lung neoplasms prostatic neoplasms colorectal neoplasms genital neoplasms urogenital neoplasms intestinal neoplasms digestive system neoplasms lymphoma leukemia multiple myeloma lymphoproliferative disorders myeloproliferative disorders lymphatic disease
plan to thrive: extending cancer survivorship care beyond the clinic

Conditions: Cancer, Breast; Cancer of Colon; Cancer of Rectum; Cancer

Summary: the purpose of this study is to test the usability of the plan to thrive smartphone application with cancer survivors. this study will involve three visits (baseline, follow-up, and feedback assessments). between the baseline and follow-up time points, patients will undergo a 90-day period in which they will engage with app content. it is hypothesized that cancer survivors in this study will find the smartphone application, plan to thrive, an acceptable and feasible way to access post-treatment information. in addition, the investigators will explore preliminary efficacy by examining changes over time in primary (patient activation, patient knowledge and adherence to follow-up care recommendations and health behaviors) and secondary outcomes \[symptom burden, health-related quality of life and patient satisfaction\].


Eligibility criteria:
inclusion criteria: * at least 18 years of age or older * prior history of cancer * completion of primary cancer treatment (i.e., surgery, chemotherapy and/or radiation; but can be receiving hormonal treatment) * have an e-mail account and reliable broadband access to the internet * able to read, understand, and speak english sufficiently to understand study questionnaires and consent form exclusion criteria: * has a medical condition with a life expectancy of fewer than 12 months * physical or cognitive disability that would prohibit them from participating in study procedures * having prior inpatient psychiatric treatment, or overt signs of, severe psychopathology (e.g., psychosis, substance dependence, suicidality)
open-label rollover study for continuing valbenazine administration for the treatment of chorea associated with huntington disease

Conditions: Chorea, Huntington

Summary: this is a phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with huntington disease.

after completion of week 156/early termination visit, participants in the us will be given the option to continue into an extended maintenance period for up to 104 weeks and participants in canada will have the option to participate in a separate open-label study (study nbi-98854-hd3022).

Eligibility criteria:
inclusion criteria: either #1 or #2 must be met for inclusion eligibility. 1. have participated in study nbi-98854-hd3005 and a. study drug dosing completion of study nbi-98854-hd3005, as demonstrated by completed study drug dosing through the follow-up visit or early terminated study nbi-98854-hd3005 for administrative reasons due to covid-19 (for example, site closure related to covid-19) 2. did not participate in study nbi-98854-hd3005 and 1. have a clinical and genetic diagnosis of huntington disease (hd) with chorea 2. be able to walk, with or without the assistance of a person or device 3. be able to read and understand english and capable of providing consent to study participation or have a legally authorized representative providing consent and the participant providing assent 4. participants of childbearing potential must agree to use contraception consistently while participating in the study until 30 days after last dose of the study treatment exclusion criteria: 1. have difficulty swallowing 2. are currently pregnant or breastfeeding 3. have a known history of long qt syndrome, cardiac tachyarrhythmia, left bundle-branch block, atrioventricular (av) block, uncontrolled bradyarrhythmia, or heart failure 4. have an unstable or serious medical or psychiatric illness 5. have a significant risk of suicidal behavior 6. have a history of substance dependence or substance (drug) or alcohol abuse, within 1 year of screening 7. have received gene therapy at any time 8. have received an investigational drug in a clinical study (other than valbenazine) within 30 days before the baseline visit or plan to use such investigational drug (other than valbenazine) during the study 9. have had a blood loss ≥550 ml or donated blood within 30 days before the baseline visit 10. have a history of severe hepatic impairment or history of protocol specified hematologic abnormalities during the course of the nbi-98854-hd3005 study 11. had a medically significant illness within 30 days before baseline, or any history of neuroleptic malignant syndrome 12. have a known hypersensitivity to any component of the formulation of valbenazine 13. for participants who did not participate in nbi-98854-hd3005: have a history of vmat2 inhibitor use within 30 days of baseline
an immunity persistence study of sabin inactivated poliovirus vaccine(vero cell) after four doses

Conditions: Poliomyelitis

Summary: this is an open and observational follow-up clinical trial based on the previous phase iii clinical trial of sabin inactivated poliovirus vaccine manufactured by sinovac biotech co. , the purpose of this study is to evaluate the immunity persistence of sipv in infants after 4 doses of vaccination.

this study is an open and observational follow-up clinical trial based on the previous phase iii clinical trial of sabin inactivated poliovirus vaccine.the purpose of this study is to evaluate the immunity persistence of sipv in infants after 4 doses of vaccination.a total of at least 450 subjects who have received 4 doses of the experimental vaccine or control vaccine will be enrolled,about 3.0ml of venous blood will be collected from each enrolled subject at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination, respectively,and the serum will be separated for neutralizing antibody detection.the antibody levels of the experimental vaccine group and the control vaccine group will be compared to evaluate the immunity persistence of sipv.

Eligibility criteria:
inclusion criteria: * subjects who have received 4 doses of experimental vaccine or control vaccine in phase ⅲ clinical trials exclusion criteria: * history of vaccination of other vaccine with poliovirus antigenic components except that of phaseⅲ clinical trial.